Moleculin Biotech, Inc. (NASDAQ:MBRX) registered a 30.90% increase, still its new closing price is 65.48% up from the company’s 1 year high of 9.58.It posted 17.09% gains in previous 5 sessions and is now the subject of analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 0 sells versus buy or better ratings. The 2 stock analysts following this company have an average price target at $9.26, with individual PT in the $9.26-$9.26 range. The shares moved at $2.33, implying that brokerage firms see shares gaining about – in twelve months time.

Moleculin Biotech, Inc. (MBRX) SEC Form 4 News

The stock is getting much attention these days as insiders are adding shares while they posted a 2.19% rise year to date. A CEO at Moleculin Biotech, Inc. (MBRX) acquired shares in a transaction closed on Wednesday November 19, 2008. Laikind Paul K bought 6,000 shares in the company at $0.64 each and collected $3,001 in proceeds. Laikind Paul K now owns 707,220 shares in the company after this transaction. A Director in the company, HALE DAVID F, disclosed a transaction on Wednesday April 16, 2008 that ended up paying $23,000 from the purchase of 10,000 shares at $2.34 per share.

Moleculin Biotech, Inc. (NASDAQ:MBRX) Upcoming Results on Tap

Moleculin Biotech, Inc. will next provide financial results for the December 2017 quarter. Stock analysts expect it to report per-share earnings of $-35.00 in that period. Sales during the quarter are predicted to arrive at $0.

Moleculin Biotech, Inc. (MBRX) Brokerage Update 

Moleculin Biotech, Inc. (MBRX) is in Oppenheimer’s research list so their analyst rating change is noteworthy. These shares were downgraded to Perform from Outperform by Oppenheimer, according to news reported on Tuesday March 31, 2009.Another important research note was issued by Rodman & Renshaw on Tuesday April 08, 2008.The firm upgraded MBRX to Mkt Outperform from Mkt Perform. Over the last six months and over the last three months, the shares of Moleculin Biotech, Inc. (MBRX), have changed -66.23% and -31.07%, respectively.